Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
09
11
2020
accepted:
09
04
2021
entrez:
12
6
2021
pubmed:
13
6
2021
medline:
13
6
2021
Statut:
epublish
Résumé
Long-term effects of continuous subcutaneous apomorphine infusion (CSAI) on health-related quality of life (HRQoL) and predictors of CSAI discontinuation are poorly known. Data from consecutive advanced Parkinson's disease patients treated in routine care were retrospectively collected over 24 months after CSAI initiation, with a focus on the 39-item Parkinson's disease questionnaire (PDQ-39). We determined predictors of CSAI discontinuation and HRQoL improvement using multiple regression analysis. Of the 110 subjects evaluated over a 2-year period, 35% discontinued CSAI. Of those who continued treatment, HRQoL remained stable with a sustained reduction in motor fluctuations. The observed effect on dyskinesias was mild and transient. Of note, patients with preexisting impulse control disorders showed an overall good tolerability. PDQ-39 was the only baseline predictor of HRQoL improvement after 2 years of treatment. The presence of dyskinesias, poorer psychological status, shorter disease duration, male sex, and worse OFF state were predictors of discontinuation. Best candidates for CSAI are patients with: (i) poor baseline HRQoL and (ii) marked motor fluctuations.
Identifiants
pubmed: 34117268
doi: 10.1038/s41531-021-00194-7
pii: 10.1038/s41531-021-00194-7
pmc: PMC8196159
doi:
Types de publication
Journal Article
Langues
eng
Pagination
50Références
Clin Neuropharmacol. 2019 Sep/Oct;42(5):172-178
pubmed: 31567642
N Engl J Med. 2013 Feb 14;368(7):610-22
pubmed: 23406026
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21
pubmed: 27979722
J Neurol. 2017 May;264(5):946-954
pubmed: 28364292
Parkinsonism Relat Disord. 1997 Apr;3(2):103-7
pubmed: 18591063
J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):372-3
pubmed: 2056329
Clin Neuropharmacol. 2015 Jul-Aug;38(4):132-4
pubmed: 26166238
Mov Disord. 2015 Apr;30(4):510-6
pubmed: 25382161
Mov Disord. 2011 Feb 15;26(3):399-406
pubmed: 21264941
Parkinsonism Relat Disord. 1999 Apr;5(1-2):69-75
pubmed: 18591123
Lancet Neurol. 2018 Sep;17(9):749-759
pubmed: 30055903
Parkinsonism Relat Disord. 2016 Feb;23:17-22
pubmed: 26709292
Mov Disord. 2018 Aug;33(8):1248-1266
pubmed: 29570866
J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):241-8
pubmed: 11796776
J Parkinsons Dis. 2020;10(s1):S65-S73
pubmed: 32651333
Psychol Health Med. 2019 Jan;24(1):27-34
pubmed: 30141703
Curr Neurol Neurosci Rep. 2020 Aug 1;20(9):44
pubmed: 32740768
RMD Open. 2019 Oct 17;5(2):e000994
pubmed: 31673410
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
J Neurol. 2016 Jun;263(6):1111-9
pubmed: 27060084
Clin Drug Investig. 2018 Apr;38(4):287-312
pubmed: 29327219
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Parkinsonism Relat Disord. 2013 Dec;19(12):1073-8
pubmed: 24051336
J Neurol Neurosurg Psychiatry. 1998 May;64(5):573-6
pubmed: 9598668
Mov Disord. 2019 Mar;34(3):353-365
pubmed: 30719763
Neurol Sci. 2019 Sep;40(9):1917-1923
pubmed: 31111272
J Neurol Sci. 2017 Jan 15;372:279-287
pubmed: 28017228
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Int Rev Neurobiol. 2017;133:499-516
pubmed: 28802930
Mov Disord Clin Pract. 2016 Aug 11;4(3):323-328
pubmed: 30363495
Neurodegener Dis. 2008;5(3-4):244-6
pubmed: 18322402
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Parkinsonism Relat Disord. 2015 Sep;21(9):1023-30
pubmed: 26189414
Parkinsonism Relat Disord. 2017 Dec;45:13-20
pubmed: 29037498
Mov Disord. 2005 Feb;20(2):151-7
pubmed: 15390035
Mov Disord. 2015 Jan;30(1):80-9
pubmed: 25488260
J Neural Transm (Vienna). 2016 Jan;123(1):31-43
pubmed: 26138439
J Parkinsons Dis. 2011;1(2):197-203
pubmed: 23934921
J Parkinsons Dis. 2020;10(1):89-97
pubmed: 31594253
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S123-5
pubmed: 22166408
Rev Neurol (Paris). 2009 Nov;165(11):845-56
pubmed: 19683776
Mov Disord. 1993 Apr;8(2):165-70
pubmed: 8474483
Mov Disord Clin Pract. 2019 Aug 16;6(7):521-530
pubmed: 31538085
Parkinsonism Relat Disord. 2019 Aug;65:86-90
pubmed: 31118162
Mov Disord. 2010 Jul 15;25(9):1131-42
pubmed: 20310033
Rev Neurol (Paris). 2014 Mar;170(3):205-15
pubmed: 24594365
Age Ageing. 1997 Sep;26(5):353-7
pubmed: 9351479
Mov Disord. 2008 Jun 15;23(8):1130-6
pubmed: 18442107
Mov Disord. 2002 Nov;17(6):1235-41
pubmed: 12465062